



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/790,488

03/01/2004

Matthew L. Sherman

AM-101314USA

9527

38199 7590 05/30/2008

HOWSON AND HOWSON/WYETH

CATHY A. KODROFF

SUITE 210

501 OFFICE CENTER DRIVE

FT WASHINGTON, PA 19034

EXAMINER

BETTON, TIMOTHY E

ART UNIT

PAPER NUMBER

1617

MAIL DATE

DELIVERY MODE

05/30/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/790,488	Applicant(s) SHERMAN ET AL.	
	Examiner TIMOTHY E. BETTON	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 April 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-38 and 45-48 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) 1-38 and 45-48 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>1 sheet, 15 April 2008</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9 April 2008 has been entered.

Applicants Remarks filed 15 April 2008 have been duly acknowledged and made of record.

The essence of applicants' arguments is drawn to the alleged improperness of the Pelosi reference drawn to unpredictability. The invention is deemed unpredictable if there is not an adequate elucidation, description, and/or explanation disclosed in the instant specification drawn specifically to embodiments replete with language readily interpretable as predictable, i.e., correlative data and cumulative results. The two Examples represented on pages 13 and 14 of the instant specification are silent in reference to findings drawn to predictability.

Thus, the Pelosi reference is concise and proper.

Further, applicants contend Dukart et al. is not properly applied based on a specific limitation drawn to a particular order in which the combination is administered.

This argument has been considered but is not found persuasive.

In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., the cited application requires a combination of an antineoplastic alkylating agent with the mTOR inhibitor. It is only in addition to that combination that a further component may be added. In the

claimed invention of this application, no antineoplastic alkylating agent is required) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Thus, by reasoning already made of record, the 112, 1st paragraph and the 102(e) rejections are maintained.

Claim Rejection- 35 USC §112, 1st paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-38, and 45-48 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the treatment of breast cancer using the claimed combinations, does not reasonably provide enablement for treatment of all neoplasms of any type. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make/use the invention commensurate in scope with these claims.

Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized in *Exparte Forman*, 230 USPQ 546 (BPAI 1986) and reiterated by the Court of Appeals in *In re Wands*, 8 USPQ2d 1400 at 1404 (CAFC 1988).

The factors to be considered in determining whether undue experimentation is required include:

- 1) the quantity of experimentation necessary
- 2) the amount of direction or guidance provided
- 3) the presence or absence of working examples
- 4) the nature of the invention
- 5) the state of the art
- 6) the relative skill of those in the art
- 7) the predictability of the art and
- 8) the breadth of the claims

The Board also stated that the level of skill in the pertinent art is high; the results of experimentation in treating a neoplasm in a mammal in need thereof are unpredictable. While all these factors are considered, a sufficient amount for a prima facie case is discussed below:

The nature of the invention

This invention relates to treatment of neoplasms.

The amount of direction or guidance provided

The amount of direction or guidance provided is insufficient in regard to a proper explanation as to how treatment directed toward neoplasms of any type. The instant specification discloses general extrapolations of the subject matter of claimed invention. Quantitative

direction and/or guidance is lacking in view of the scope and variable susceptibilities of claimed invention.

The quantity of experimentation necessary and state of the art

The quantity of experimentation necessary is high. Further studies, research and development are required due to insufficient evidence in the instant specification to support a proper scope of enablement of current invention. The instant specification discloses no such examples of experimentation. The experimentation yields no quantifiable evidence (comparative data of disclosure of studies on various etiologies of neoplasms or neoplasm types via due experimentation).

The presence or absence of working example

A practicing working example disclosing an embodiment of the central issue of invention directed toward a method of treating any neoplasm type is absent. One of ordinary skill in the pertinent art would not be readily inclined to reasonably envision the scope of enablement in view of the two examples disclosed within the instant specification.

The predictability in the art

The level of unpredictability is high in the art. The instant specification does not support

the due experimentation necessary for the embodiments of claimed invention to be predictable.

For example, the term neoplasm/solid tumor encompasses three distinctly different categories of tumors: (1) sarcomas, those that arise from connective or supporting tissues, such as bone or muscle; (2) carcinomas, those that arise from glandular tissues and epithelial cells; and (3) lymphomas, those that arise from the lymphoid organs, such as the lymph nodes, spleen or thymus. There are distinct etiologies and pathophysiological differences between these three categories of solid tumor would not have imbued the skilled artisan with a reasonable expectation of success in treating any one or more of these neoplasm types.

The pertinent art still deems neoplastic conditions/solid tumors as unpredictable in their clinical behavior (Giuseppe et al., Pulmonary Epithelial-Myoepithelial Tumor of Unproven Malignant Potential: Report of a case and Review of the Literature, Mod Pathol (2001), 14(5): 521-526, printed pages 1-8, especially page 2, immediate paragraph under Full Table).

Claim Rejection- 35 USC §102(e)

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for

Art Unit: 1617

purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

The applied reference has a common inventor with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

Claims 1- 38 and 45-48 are rejected under 35 U.S.C. 102(e) as being anticipated by Dukart et al. (USPGPUB 2003/0008923 A1).

Dukart et al. teach neoplasms generally or four specific neoplastic conditions, i.e., colon, neuroblastoma, glioblastoma, rhabdomyosarcoma [0009], [0010], [0057].

Dukart et al. teach CCI-779 [0006, 0007].

Dukart et al. teach 42-O- (2-hydroxy) ethyl rapamycin ([0032, 0034], (referenced claims 30 and 34)).

Dukart et al. teach letrozole [0064].

Dukart et al. teach a practicing method of administering subtherapeutically effective amounts (page 7, patented claim 27).

Dukart et al. teach neoplasms generally or four specific neoplastic conditions, i.e., colon, neuroblastoma, glioblastoma, rhabdomyosarcoma [0009], [0010], [0057].

Dukart et al. also teach renal cancer, soft tissue sarcoma, breast cancer, neuroendocrine tumor of the lung, cervical cancer, uterine cancer, head and neck cancer, glioma, non-small cell lung

Art Unit: 1617

cancer, prostate cancer, pancreatic cancer, lymphoma, melanoma, small cell lung cancer, ovarian cancer, colon cancer, esophageal cancer, gastric cancer, leukemia, colorectal cancer, and unknown primary cancer (page 7, patented claims 1-22).

Dukart et al. teach variable pharmaceutical combinations and combination/formulation therapy (Abstract, [0012], [0058]).

Dukart et al. teach compositions and products which fully anticipate the subject matter of claimed invention. As shown above, Dukart et al. teach the exact therapeutic agents as disclosed in claimed invention.

Thus, Dukart et al fully anticipates the central issue of claimed invention.

The claim is anticipated by the reference. No question of obviousness is present. In other words, for anticipation under 35 USC 102, the reference must teach every aspect of the claimed invention either explicitly or impliedly. Any feature not directly taught must be inherently present.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Timothy E. Betton whose telephone number is (571) 272-9922. The examiner can normally be reached on Monday-Friday 8:30a - 5:00p.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published

Art Unit: 1617

applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Shengjun Wang/

5/9/2008

Primary Examiner, Art Unit 1617

TEB

Application/Control Number: 10/790,488
Art Unit: 1617

Page 10